NASDAQ:FBIO
Fortress Biotech Stock News
$1.87
-0.110 (-5.56%)
At Close: May 22, 2024
Fortress Reports Positive Data And Other News: The Good, Bad And Ugly Of Biopharma
12:29am, Monday, 31'st Aug 2020
Fortress Biotech reports positive data from CUTX-101. Lipocine suffers setback on Tlando front.
Landec and Evolent Health See Activist Action
10:09pm, Friday, 28'th Aug 2020
Legion Partners revealed that it owns 2,904,340 shares of Landec, a maker of packaged foods and biomaterials, and Engaged Capital initiated a 9.99% stake in health-care-services firm Evolent, equal to
Fortress Biotech Investor Presentation - Slideshow
08:41am, Friday, 28'th Aug 2020
The following slide deck was published by Fortress Biotech, Inc. in conjunction with this event..
Global Safety Switches Industry (2020 to 2027) - Market Trajectory & Analytics - ResearchAndMarkets.com
12:00am, Friday, 28'th Aug 2020
The
Fortress Biotech Announces Pricing of Series A Preferred Stock Offering
12:30am, Thursday, 27'th Aug 2020
Fortress Biotech, Inc. (Common Stock: Nasdaq: FBIO) (Preferred Stock: Nasdaq: FBIOP) (“Fortress”), an innovative biopharmaceutical company, today announced that
New Fortress Energy Declares Inaugural Common Stock Dividend
12:00am, Thursday, 27'th Aug 2020
New Fortress Energy Inc. (NASDAQ:NFE) (“New Fortress” or the “Company”) announced today that its Board of Directors (the “Board”) has declared a third
B.Riley FBR Believes Fortress Biotech (NASDAQ: FBIO) Still Has Room to Grow - Markets
03:06pm, Friday, 21'st Aug 2020
B.Riley FBR analyst Mayank Mamtani reiterated a Buy rating on Fortress Biotech (FBIO – Research Report) today and set a
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 17)
Catalent Inc (NYSE: CTLT)
CureVac N.V. (NASDAQ: CVAC) (follow-on buying after a 250% advance on its debut Friday...
NEW YORK, Aug. 12, 2020 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative revenue-generating company focused on acquiring, developing and commercializing or mon
Fortress Biotech Reports Second Quarter 2020 Financial Results and Recent Corporate Highlights
08:30pm, Monday, 10'th Aug 2020
Product revenue for the first six months of 2020 increased 50% year-over-year to $21.4 million Agreement executed with Columbia University to develop novel oligonucleotide platform for the treatment
Qiagen, Pandion See Activist Actions
12:15am, Saturday, 08'th Aug 2020
Davidson Kempner Capital Management reported an 8% interest the Netherlands-based molecular testing firm Qiagen. Boxer Capital now owns 2,107,513 shares of newly public clinical-stage biopharmaceutica
LD Micro-Announces Preliminary List of Presenters for the LD 500.
07:34pm, Wednesday, 05'th Aug 2020
LOS ANGELES, CA / ACCESSWIRE / August 5, 2020 / LD Micro today announced the initial list of companies slated to present at the upcoming LD 500, taking place September 1st-4th, 2020, exclusively onlin
49 Public Companies to Present at the SNN Network Virtual Conference on August 3-6, 2020
12:00pm, Monday, 03'rd Aug 2020
LOS ANGELES, CA / ACCESSWIRE / August 3, 2020 / The SNN Network Virtual Conference will take place on August 3rd \\- 6th, 2020, where 49 SmallCap, MicroCap and NanoCap public companies will be present
Rolling submission of New Drug Application to the FDA for CUTX-101 on track to begin in the fourth quarter of 2020NEW YORK, July 31, 2020 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“
Cyprium Therapeutics, a Fortress partner company, is developing CUTX-101 for Menkes disease A rolling submission of a New Drug Application to the FDA is expected to begin in the fourth quarter of 202
